Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETINO 2011
2024-517275-21-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan in retinoblastoma (Rb) (3 arms), sponsored by Institut Curie. Primary endpoint: Ocular preservation and avoidance of external beam radiotherapy at 18 months. Planned start Sep 2024; status: authorised.
02
Drugs
melphalan
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on 2024-517275-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517275-21-00.